相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Marie Kostine et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases
Yun Liu et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)
Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment
Yue-Bei Luo et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems
Rulan Ma et al.
BMC CANCER (2021)
Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report
Li Shen et al.
FRONTIERS IN IMMUNOLOGY (2021)
Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases
Ranjan Pathak et al.
ONCOLOGIST (2021)
An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors
Roberta Esposito et al.
BIOMOLECULES (2021)
Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report
Antonio Portoles Hernandez et al.
CARDIOVASCULAR DIAGNOSIS AND THERAPY (2021)
Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma
Jae-Won Hyun et al.
CLINICAL LUNG CANCER (2020)
Cardiovascular megnetic resonance in immune checkpoint Inhibitor-associated myocarditis
Lili Zhang et al.
EUROPEAN HEART JOURNAL (2020)
A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies
Christina W. Guo et al.
EUROPEAN JOURNAL OF CANCER (2020)
Management of Immunotherapy-Related Toxicities, Version 1.2020 Featured Updates to the NCCN Guidelines
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
Jun Shao et al.
BIOSCIENCE REPORTS (2020)
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
Nicolas Palaskas et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma
Qian Xing et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities
Yves Allenbach et al.
AUTOIMMUNITY REVIEWS (2020)
Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database
Shiori Hasegawa et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
Bairavi Shankar et al.
JAMA ONCOLOGY (2020)
Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases
Suheil Albert Atallah-Yunes et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis
Hayato So et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2019)
Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis
Brandon T. Larsen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective
Neil M. Steven et al.
RHEUMATOLOGY (2019)
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Filipe Martins et al.
LANCET ONCOLOGY (2019)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Javid J. Moslehi et al.
LANCET (2018)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
Karthik Suresh et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm
C. L. Haddox et al.
ANNALS OF ONCOLOGY (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma
Juliane Behling et al.
MELANOMA RESEARCH (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity
Marion Escudier et al.
CIRCULATION (2017)
Myasthenic crisis and polymyositis induced by one dose of nivolumab
Toshihiro Kimura et al.
CANCER SCIENCE (2016)
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
Elisa Gonzalez-Rodriguez et al.
ONCOLOGIST (2016)
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis
Mizuki Nishino et al.
JAMA ONCOLOGY (2016)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Claire F. Friedman et al.
JAMA ONCOLOGY (2016)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
分享论文
